KROS Keros Therapeutics, Inc.
$11.43▲ +0.84%
Healthcare
Other
After hours
$11.43▲ +0.00%
Oct 27, 4:00 PM ET
Volume 148.5K
Avg Volume (10D) 146.1K
Key Metrics & Fundamentals
Market Cap
$226.53M
P/E Ratio
4.6
Div Yield
0.00%
52W Range
9.69 - 22.55
% vs 50 MA
1.60%
% vs 200 MA
-6.22%
RSI-14
52.7
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.06
Free Cash Flow
-$20.58M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$32.82M
COGS
–
Operating Exp
$30.94M
Operating Income
-$30.94M
EBIT
-$30.94M
Pretax Income
-$28.71M
Net Income
-$28.71M
EPS (Diluted)
-1.45
Price & Volume History
Loading chart…
Recent News
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
MarketBeat · Oct 22, 2026 7:04 PM ET
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
CNW Group · Oct 20, 2026 8:59 AM ET
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
Zacks · Oct 7, 2026 1:30 PM ET
Keros Therapeutics Expects $20 Million Milestone Payment From Takeda
MT Newswires · Sep 29, 2026 10:36 AM ET
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Zacks · Sep 29, 2026 9:17 AM ET
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
GlobeNewswire · Sep 29, 2026 8:00 AM ET
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
GlobeNewswire · Sep 28, 2026 8:00 AM ET
Keros Therapeutics Approves $5 Million Share Buyback
MT Newswires · Sep 8, 2026 4:21 PM ET
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
GlobeNewswire · Sep 8, 2026 4:01 PM ET
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Zacks · Sep 2, 2026 11:30 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See KROS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.